Spinal Cord Stimulation Holds Promise for Chronic Pain
By Lori Solomon HealthDay Reporter
WEDNESDAY, Nov. 20, 2024 -- Spinal cord stimulation (SCS) for treatment of chronic pain in the back and/or lower extremities is associated with greater improvements in pain compared with conventional medical management (CMM), according to a review published online Nov. 14 in JAMA Network Open.
Frank J. P. M. Huygen, Ph.D., M.D., from Erasmus Medical Center in Rotterdam, Netherlands, and colleagues conducted a systematic literature review and network meta-analysis to evaluate the efficacy of SCS therapies compared to CMM.
Based on 13 included studies (1,561 patients), the researchers found that both conventional and novel SCS therapies were associated with superior efficacy versus CMM in responder rates for pain reduction in the back (conventional SCS: odds ratio [OR], 3.00; novel SCS: OR, 8.76), pain intensity in the back (conventional SCS: mean difference [MD], −1.17; novel SCS: MD, −2.34), pain intensity in the leg (conventional SCS: MD, −2.89; novel SCS: MD, −4.01), and the EQ-5D index score (conventional SCS: MD, 0.15; novel SCS: MD, 0.17). Conventional SCS was superior to CMM for functional disability (MD, −7.10).
"Our study provides important insights for clinical decision-making as well as assessment by health technology agencies based on a more representative evidence base and a more inclusive analytical framework than that reported by prior reviews comparing SCS technologies," the authors write.
Several authors disclosed ties to Medtronic.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-21 06:00
Read more
- Prior Authorization Leads to Radiation Oncology Treatment Delays, Patient Harm
- More of America's Pets Are Overdosing on Stray Coke, Meth
- Mystery Illness Kills Dozens in Congo
- Texas Sues NY Doctor for Prescribing Abortion Pill by Telehealth
- Findings from Minzasolmin Proof-of-Concept ORCHESTRA Study Shape Next Steps in UCB Parkinson’s Research Program
- FDA: Veozah, First Hormone-Free Hot Flash Drug, Issued Black Box Warning
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions